Print Page   |   Contact Us   |   Sign In   |   Join Today
Federal Policy
Share |

Virginia Bio works effectively on a range national policy issues impacting our members and our industry because of our close working relationship with leading national organizations BIO, PhRMA, MDMA and AdvaMed. The skilled and experienced staff at these Washington-based organizations help us to stay apprised of issues and events, to participate in the formation and advocacy for specific policies, to provide firm and state level feedback on federal legislative and administrative policy issues, and to help our members make known their positions and concerns.


BIO Government Relations


Advamed Issues


Virginia Bio organizes the participation of its members in yearly national "fly in” days to Washington, DC for BIO, AdvaMed and the "We Work for Health” coalition.  Participating members travel to Washington and join their counterparts from across the United States in briefings on critical and pressing federal issues. They then visit members of the Virginia Congressional delegation and their staffs to make their voices heard on these issues and issues of individual interest.


Virginia Bio throughout the year provides information and responds to requests for information from legislative and executive policy makers, and helps put them in touch with our members in networking events, and forums and one on one. We build long term relationships with legislative and executive policy makers with our organization and our members. Year round we make visits and invitations to federal policy makers. We assist members in making contact with members of Congress and regulators, and help them get the help they need on individual issues.

Virginia Bio works for federal policies that:


  •  Strongly support basic and translational research, such as the levels and conditions of National Institutes of Health (NIH) funding and SBIR/STTR funding;
  • Provide an effective and efficient regulatory framework and a well-equipped and accountable FDA, for example the FDASIA user fee legislation and adequate FDA funding and performance accountability;
  •  Provide fair reimbursement for drugs, devices and diagnostics and patient access under federal payor programs like Medicare and Medicaid;
  •  Assure taxes and regulations are sufficient and fair, but do not disproportionately or destructively impact our member companies or their industry, or the innovation ecosystem on which progress in health care rests; and,
  •  Strengthen and spread meaningful and effective intellectual property protection, including US patent laws and international treaties involving Intellectual Property (IP).

Find and/or contact Virginia Senators or Representatives

more Events

Virginia Bioscience Commercialization Luncheon- September 2017

Premium Members

Membership Software Powered by YourMembership  ::  Legal